Drug Discovery

inhibitors

Peptide Covalent Inhibitors Targeting Protein-Protein Interactions

Covalent drugs refer to those drug molecules that form strong bonds with receptors through the formation of covalent bonds. It all began with aspirin in 1899, gained prominence with ibrutinib in […]

deuterated drugs

Deuterated Drugs Research Progress

What are Deuterated Drugs? Deuterated drugs are medications obtained by substituting hydrogen atoms at specific positions on drug molecules with deuterium atoms. The most widely used application involves replacing carbon-hydrogen (C-H) bonds with […]

Cyclic Peptide Inhibitors of KRAS

Challenges and Advantages in the Development of Cyclic Peptide Inhibitors of KRAS

Over the past several decades, direct inhibition of the RAS family of oncogenic proteins has been a significant challenge in the field of drug development. Despite accounting for approximately 30% […]

antibody drug conjugate

ADC Cleavable Linker: Classification and Mechanism of Action

Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances […]

siRNA Design

Optimization of siRNA Design

The length of siRNA is 7-8 nm, the diameter is 2-3 nm, the molecular weight is 13-14 kDa, and it is hydrophilic. Therefore, unmodified and naked siRNA cannot passively cross […]

ADC targets

Nectin-4: A New Target of ADC

Overview of Nectin Nectin, a cell adhesion molecule belonging to the Immunoglobulin (Ig) superfamily, is a homologue of poliovirus receptor (PVR/CD155). It also known as poliovirus receptor-associated protein Receptor Related Protein (PVRL). […]

Peptide-drug Conjugate

Overview of Peptide-drug Conjugate

The concept of drug conjugates originated in the early 20th century. In 1910, Paul Ehrlich proposed the “Magic Bullet” theory, which aimed to describe the concept of a drug that […]

antibody drug conjugate

FDA Approved Antibody-Drug Conjugates (ADCs) By 2023

Antibody Drug Conjugate (ADC) is a complex formed by linking cytotoxic drugs to tumor-targeting monoclonal antibodies. It combines the characteristics of targeted drugs and chemotherapy drugs to achieve precise treatment. The concept […]

Telomere Targeting Chimera

Literature Interpretation (JACS): Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins

Today I would like to share with you an article published in JACS titled “Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins”. This article developed a nucleotide-based […]

drug discovery

Research Progress of Small Molecule Drugs Targeting PD-1/PD-L1

Immunotherapy, which uses immune pathways to treat cancer, is rapidly becoming an accepted cancer treatment after surgery, chemotherapy and radiation. Checkpoint blocking using monoclonal antibodies against cytotoxic T lymphocyte-associated protein […]